IL105141A - History and metabolites of hydroxylated doxesuzin as anti-atherosclerotic substances - Google Patents

History and metabolites of hydroxylated doxesuzin as anti-atherosclerotic substances

Info

Publication number
IL105141A
IL105141A IL10514193A IL10514193A IL105141A IL 105141 A IL105141 A IL 105141A IL 10514193 A IL10514193 A IL 10514193A IL 10514193 A IL10514193 A IL 10514193A IL 105141 A IL105141 A IL 105141A
Authority
IL
Israel
Prior art keywords
medicament
compound
formula
doxazosin
atherosclerosis
Prior art date
Application number
IL10514193A
Other languages
English (en)
Hebrew (he)
Other versions
IL105141A0 (en
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IL105141A0 publication Critical patent/IL105141A0/xx
Publication of IL105141A publication Critical patent/IL105141A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L2924/00—Indexing scheme for arrangements or methods for connecting or disconnecting semiconductor or solid-state bodies as covered by H01L24/00
    • H01L2924/15—Details of package parts other than the semiconductor or other solid state devices to be connected
    • H01L2924/181—Encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL10514193A 1992-04-01 1993-03-23 History and metabolites of hydroxylated doxesuzin as anti-atherosclerotic substances IL105141A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86171492A 1992-04-01 1992-04-01

Publications (2)

Publication Number Publication Date
IL105141A0 IL105141A0 (en) 1993-07-08
IL105141A true IL105141A (en) 1998-10-30

Family

ID=25336560

Family Applications (1)

Application Number Title Priority Date Filing Date
IL10514193A IL105141A (en) 1992-04-01 1993-03-23 History and metabolites of hydroxylated doxesuzin as anti-atherosclerotic substances

Country Status (17)

Country Link
US (1) US5543411A (ko)
EP (1) EP0564093B1 (ko)
JP (1) JPH0624989A (ko)
KR (1) KR0137927B1 (ko)
AT (1) ATE187069T1 (ko)
AU (1) AU660359B2 (ko)
CA (1) CA2092983C (ko)
DE (1) DE69327128T2 (ko)
DK (1) DK0564093T3 (ko)
ES (1) ES2139624T3 (ko)
GR (1) GR3032373T3 (ko)
HU (1) HU225113B1 (ko)
IL (1) IL105141A (ko)
MX (1) MX9301824A (ko)
NZ (1) NZ247307A (ko)
PT (1) PT564093E (ko)
ZA (1) ZA932307B (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120302A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
US6177430B1 (en) 1997-03-27 2001-01-23 Pfizer Inc Use of α1-adrenoreceptor antagonists in the prevention and treatment of benign prostatic hyperplasia
IL120303A0 (en) * 1996-03-27 1997-06-10 Pfizer Use of alpha1-adrenoreceptor antagonists in the prevention and treatment of cancer
WO2002024114A2 (en) * 2000-09-25 2002-03-28 Cohesion Technologies, Inc. Resorbable anastomosis stents and plugs
US20050165428A1 (en) * 2000-09-25 2005-07-28 Franco Kenneth L. Absorable surgical structure
KR101119387B1 (ko) 2003-07-18 2012-03-07 하마마츠 포토닉스 가부시키가이샤 절단방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB271997A (en) * 1926-04-16 1927-06-09 Morris Engines Coventry Ltd Improvements relating to the driving of cam or other auxiliary shafts in internal combustion engines
US4188390A (en) * 1977-11-05 1980-02-12 Pfizer Inc. Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines
GB8506174D0 (en) * 1985-03-09 1985-04-11 Pfizer Ltd 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives
US4758569A (en) * 1987-08-26 1988-07-19 Pfizer Inc. Doxazosin as an anti-atherosclerosis agent

Also Published As

Publication number Publication date
DK0564093T3 (da) 2000-03-27
HU225113B1 (en) 2006-06-28
IL105141A0 (en) 1993-07-08
AU3562993A (en) 1993-10-07
MX9301824A (es) 1994-02-28
ATE187069T1 (de) 1999-12-15
JPH0624989A (ja) 1994-02-01
KR930021203A (ko) 1993-11-22
HU9300947D0 (en) 1993-06-28
US5543411A (en) 1996-08-06
DE69327128D1 (de) 2000-01-05
HUT65849A (en) 1994-07-28
GR3032373T3 (en) 2000-04-27
CA2092983A1 (en) 1993-10-02
AU660359B2 (en) 1995-06-22
CA2092983C (en) 1996-12-31
NZ247307A (en) 1997-06-24
ES2139624T3 (es) 2000-02-16
PT564093E (pt) 2000-04-28
ZA932307B (en) 1994-09-30
EP0564093A1 (en) 1993-10-06
DE69327128T2 (de) 2000-04-20
EP0564093B1 (en) 1999-12-01
KR0137927B1 (ko) 1998-05-15

Similar Documents

Publication Publication Date Title
KR0150631B1 (ko) 비스(3,5-디-tert-부틸-4-히드록시페닐티오)메탄 함유 콜레스테롤 저하제겸 아테롬성 동맥 경화증 치료제
EP0741567B1 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
US6716875B1 (en) Synergistic therapeutic compositions of ACE and renin inhibitors and methods
CA1323572C (en) Doxazosin as an anti-atherosclerosis agent
US8343979B2 (en) Use of alkanoyl L-carnitine for the treatment of erectile dysfunction
Cutler Effect of antihypertensive agents on lipid metabolism
US5543411A (en) Hydroxylated metabolites and derivatives of doxazosin as anti-atherosclerosis agents
CA2060789C (en) Use of tenidap to reduce total serum cholesterol, ldl cholesterol and triglycerides
KR950703961A (ko) 양성 전립선 비후증과 동맥경화증 치료방법 및 이를 위한 (+)독사조신 조성물
EP0319288B1 (en) dl-5-[(2-benzyl-3,4-dihydro-2H-benzopyran-6-yl)methyl]thiazolidine-2,4-dione as an anti-atherosclerosis agent
JP2003503342A (ja) ＭＴＰ阻害剤とＨＭＧ−ＣｏＡ還元酵素阻害剤との組み合わせ並びに薬剤におけるその使用
US4582832A (en) Trimazosin as an anti-atherosclerosis agent
Mantero et al. Effect of atenolol and metoprolol on the anticoagulant activity of acenocoumarin.
JP2004250442A (ja) エンドセリン血中濃度低下剤
JPH0573728B2 (ko)

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees